BOOM31 Mar 2020 11:32
“A successful outcome from this trial in COVID-19 patients would be a major breakthrough in the fight against this coronavirus pandemic."
While the company is pausing work on the almost-complete phase II trial of COPD sufferers to protect this vulnerable patient population, the early signs were that SNG001 provided “clinical benefit in lung function”.
In the update, the company said that since the outbreak it had been approached by - and is in discussion with - a number of other medical, scientific, and governmental bodies at home and around the world “seeking to investigate novel therapeutics in this area”.